Your browser version may not work well with NCBI's Web applications. More information here...
1: J Clin Invest. 2008 Oct;118(10):3420-30.
Related Articles, Links
Click here to read Click here to read Click here to read Click here to read
Comment in:
Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression.

Matsushita T, Yanaba K, Bouaziz JD, Fujimoto M, Tedder TF.

Department of Immunology, Duke University Medical Center, Durham, North Carolina, USA.

EAE is a mouse T cell-mediated autoimmune disease of the CNS used to model the human condition MS. The contributions of B cells to EAE initiation and progression are unclear. In this study, we have shown that EAE disease initiation and progression are differentially influenced by the depletion of B cells from mice with otherwise intact immune systems. CD20 antibody-mediated B cell depletion before EAE induction substantially exacerbated disease symptoms and increased encephalitogenic T cell influx into the CNS. Increased symptom severity resulted from the depletion of a rare IL-10-producing CD1dhiCD5+ regulatory B cell subset (B10 cells), since the adoptive transfer of splenic B10 cells before EAE induction normalized EAE in B cell-depleted mice. While transfer of regulatory B10 cells was maximally effective during early EAE initiation, they had no obvious role during disease progression. Rather, B cell depletion during EAE disease progression dramatically suppressed symptoms. Specifically, B cells were required for the generation of CD4+ T cells specific for CNS autoantigen and the entry of encephalitogenic T cells into the CNS during disease progression. These results demonstrate reciprocal regulatory roles for B cells during EAE immunopathogenesis. The therapeutic effect of B cell depletion for the treatment of autoimmunity may therefore depend on the relative contributions and the timing of these opposing B cell activities during the course of disease initiation and pathogenesis.

Publication Types:
PMID: 18802481 [PubMed - indexed for MEDLINE]

PMCID: PMC2542851